ARTICLE
23 February 2022

It's The Little Things: FDA Issues A Warning Letter For Improper Drug Listing

AG
Arnall Golden Gregory

Contributor

Arnall Golden Gregory
In a nod to Alice Cooper's 2000 song, "It's the Little Things" (or, for literary fans, Robert Frost's quote, "It's the little details that are vital; little things make big things bigger"), ...
United States Food, Drugs, Healthcare, Life Sciences

In a nod to Alice Cooper's 2000 song, "It's the Little Things" (or, for literary fans, Robert Frost's quote, "It's the little details that are vital; little things make big things bigger"), the Food and Drug Administration's Center for Drug Evaluation and Research issued a Warning Letter to a drug company for improper drug listing information.1

Highlights

  • FDA wrote that the company provided an incorrect active ingredient (conjugated estrogens vs. esterified estrogens) when it submitted its electronic listing file.
  • The agency noted it sent the company two letters, one about the listing errors and another about removing the products from FDA's Online NDC Directory.
  • FDA stated, "Complete, accurate and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety."
  • As is common practice with Warning Letters, the company must respond within 15 working days or face an increased enforcement risk.

AGG Observations

  • FDA cares about the little things. We do not mean to suggest that listing deficiencies are "little," but we typically see the issuance of Warning Letters for quality-related concerns, promotional deficiencies, regulatory classifications matters, or public health risks. This issue here was an administrative, submission error.
  • The previous (failed) attempts by FDA to have the company voluntarily comply did not help. Don't ignore FDA.
  • The type of product at issue could have been of particular concern to FDA but improper listing, regardless of the product, is unlawful.
  • As noted, this type of Warning Letter is not typical. However, it shows FDA will enforce this type of unlawful activity by issuing a public letter, and it reminds industry that, at times, it pays to sweat the small stuff.

Footnote

1. See www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eci-pharmaceuticals-llc-625254-02032022.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More